Kelonia Therapeutics, Inc.

Scholar Rock, Inc.

Andrew Avery

Molly R Perkins

Kevin M Friedman

Stephen L Sazinsky

Emily Thompson Beura

Cory Ahonen

Connor S Dobson

Shannon G Contrastano

Gregory John Carven

Thomas Schurpf

Justin W Jackson

Stefan Wawersik

Abhishek Datta

Alan J Buckler

Christopher Littlefield

Caitlin Stein

Matthew Salotto

Allan Capili

Kevin B Dagbay

Christopher Chapron

Constance Martin

Susan Lin

Anthony Cooper

Anthony A Cooper

Gregory J Carven

Alan Buckler

The present disclosure provides compositions and methods comprising recombinant particles suitable for specifically delivering one or more chimeric antigen receptors to immune effector cells in vivo.

Compositions for treating cancer

The present disclosure provides compositions comprising antigen binding polypeptides. More particularly, the disclosure relates to polypeptides comprising antibodies or antigen binding fragments thereof, nucleic acids encoding the polypeptides, and vectors for expressing the same.

Antigen binding polypeptides

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors

Isoform-selective TGFB1 inhibitors and use thereof

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGF&#x3b2;1 with high potency. Related compositions, methods and therapeutic use are also disclosed.

Isoform-selective TGF&#x3b2;1 inhibitors and use thereof

Growing community of inventors

Lebanon, NH, United States of America

Andrew Avery